1/12
10:07 pm
cytk
CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten) [Yahoo! Finance]
Low
Report
CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten) [Yahoo! Finance]
1/9
12:02 pm
cytk
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
1/8
10:05 am
cytk
Cytokinetics (NASDAQ:CYTK) was given a new $90.00 price target on by analysts at Morgan Stanley.
Low
Report
Cytokinetics (NASDAQ:CYTK) was given a new $90.00 price target on by analysts at Morgan Stanley.
1/8
08:59 am
cytk
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
1/7
08:47 am
cytk
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
1/5
04:00 pm
cytk
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/2
09:05 am
cytk
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
12/30
09:57 am
cytk
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
12/22
05:36 pm
cytk
Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]
Low
Report
Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]
12/22
02:08 pm
cytk
Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.
12/22
01:07 pm
cytk
Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/22
01:07 pm
cytk
Cytokinetics (NASDAQ:CYTK) was given a new $83.00 price target on by analysts at Leerink Partners.
Medium
Report
Cytokinetics (NASDAQ:CYTK) was given a new $83.00 price target on by analysts at Leerink Partners.
12/22
09:49 am
cytk
Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript [Seeking Alpha]
Medium
Report
Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript [Seeking Alpha]
12/22
09:13 am
cytk
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Low
Report
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
12/22
08:07 am
cytk
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/22
08:02 am
cytk
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a "buy" rating on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a "buy" rating on the stock.
12/22
08:02 am
cytk
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a "market outperform" rating on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a "market outperform" rating on the stock.
12/22
07:18 am
cytk
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/22
07:03 am
cytk
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/22
06:01 am
cytk
Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/21
04:58 pm
cytk
Cytokinetics set to battle Bristol Myers as FDA approves heart drug [Yahoo! Finance]
Medium
Report
Cytokinetics set to battle Bristol Myers as FDA approves heart drug [Yahoo! Finance]
12/20
09:38 am
cytk
Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? [Yahoo! Finance]
Medium
Report
Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? [Yahoo! Finance]
12/19
07:08 pm
cytk
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms [Yahoo! Finance]
Medium
Report
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms [Yahoo! Finance]
12/19
04:00 pm
cytk
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Medium
Report
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
12/19
11:24 am
cytk
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]
Low
Report
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]